title: [Urology].
abstract: In prostatic cancer, PSA velocity is a reliable sign of cancer agressivity. In the metastatic prostatic cancer, there is no difference on survival between an early and late hormonal treatment. In the invasive bladder cancer néo-adjuvant chemotherapy offers a light advantage. In the kidney cancer, anti-angiogenic agents increase the survival. In the non neurogenic overactive bladder, no studies have led to relevant results in using antimuscarinic agent in the first line. The 5 phophodiesterase inhibitors used in the treatment of erectile dysfunction are also effective in the treatment of trouble induced by benign prostatic hyperplasia.
authors.affiliation: Service d'urologie, CHUV, 1011 Lausanne. Patrice.Jichlinski@chuv.ch
authors.forename: Patrice
authors.initials: P
authors.lastname: Jichlinski
authors.forename: Marc
authors.initials: M
authors.lastname: Wisard
mesh_terms: D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000097:blood / Q000628:therapy*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D017430:Prostate-Specific Antigen